 | This article was considered for deletion, and requires cleanup according to the discussion .(March 2011) |
 |
Dr R. K Kamboj (Rajender K Kamboj, Rajender Kamboj, Raj Kamboj) is an Indian Pharmaceutical scientist in the area of drug discovery. He was born in 1955 to Sh.Karta Ram Kamboj at Village Fatehpur, Yamunanagar district, Haryana.
He did his M.Sc in Biological Sciences in 1977. He joined the University of Adelaide, Australia in 1981 and completed his Ph.D [1] in March 1986. During his doctoral studies at the University of Adelaide (1981–1986), Kamboj published his researches in Plant Physiology. Kamboj's doctoral thesis was about Biochemical Studies on pollen and pollen-pistil interaction in `Petunia hybrida`. [2]
After completing his Ph.D, Dr Kamboj continued to work as research scientist in Australia till 1991. Thereafter, he moved to Canada to join Allelix Biopharmaceuticals Inc (a part of NPS Pharmaceuticals, Inc, Toronto ), as its Vice President and Chief Scientific Officer. At Allelix, Kamboj was entrusted with the primary responsibility of managing its drug discovery programs. After working about 12 years with Allelix, Dr Kamboj joined Xenon Genetics Inc, Vancouver as its Vice President for Drug Discovery. [3] In both the companies named above, Dr Kamboj was instrumental in taking the companies from the inception of the drug discovery group all the way to multiple licensing transactions and collaborations.
Dr Kamboj left Xenon Genetics Inc. in June 2008 to join Lupin Limited, a medium-sized, but aggressive transnational pharmaceutical company from India, where he was appointed President of New Chemical Entity (NCE) Research of Lupin Limited. [4] In the same year, Kamboj was also appointed president of the Novel Drug Discovery and Development of Lupin Limited . [5]
Dr Kamboj's experience includes contributions to business development, licensing products and technologies, mergers and acquisitions and corporate development activities. He holds over forty (40) U.S. patent applications (filed and issued), covering the discovery and use of a number of human genes. He is the author/co-author of over 90 research articles/papers in the field of biomedical field. His career spans more than 29 years in research, 16 years of which is in pharmaceutical industrial R&D setting.
Dr Kamboj is currently a member of the working group on New TB Drugs Team, India.
Dr Kamboj is also a member of the Market Advisory Groups (MAG) of the Asia Pacific Trade Council of British Columbia, Canada. [6]
Frank Edward Young was an American physician who served as Commissioner of Food and Drugs from 1984 to 1989 and later as a Deputy Assistant Secretary in the United States Department of Health and Human Services. In 2013 he joined Braeburn Pharmaceuticals as Executive Vice President, Clinical and Regulatory Affairs. In 2018, he became the Executive Vice President of Clinical and Regulatory Affairs at TissueTech Inc.
Claude H. Nash was CEO of Bloodstone Ventures plc. from 2007 to 2010. From 2004 to 2006 he was vice president, research and development at the University of Maryland Biotechnology Institute. He previously cofounded, and was CEO and chairman of, ViroPharma Incorporated, a pharmaceutical company. Before founding ViroPharma, Nash was vice president of infectious disease and cancer research at the Schering-Plough Research Institute.
Charles Thomas Caskey, also known as C. Thomas Caskey, was an American internist who has been a medical Geneticist and biomedical researcher and entrepreneur. He was a Professor of Molecular and Human Genetics at Baylor College of Medicine, and served as editor of the Annual Review of Medicine from 2001 to 2019. He was a member of the editorial boards of the Proceedings of the National Academy of Sciences, Science, the Encyclopedia of Molecular Medicine and numerous other medical and scientific journals.
Jonathan S. Dordick is an institute professor of chemical and biological engineering at Rensselaer Polytechnic Institute and holds joint appointments in the departments of biomedical engineering and biological sciences. In 2008 he became director of the Center for Biotechnology and Interdisciplinary Studies. In 2012 Dordick became the vice president for research at RPI. He became Special Advisor to the RPI President for Strategic Initiatives in 2018,
Jan A. J. Schuurkes is a Dutch biologist and gastrointestinal researcher.
Sung Wan Kim was a South Korean-American academic who worked as a distinguished professor of pharmaceutics and pharmaceutical chemistry at the University of Utah. He is the founder and co-director of the University of Utah's Center for Controlled Chemical Delivery.
Nicholas Gordon Martin is an Australian behavior geneticist who has published over 1300 peer-reviewed articles on topics including the heritability of religion and intelligence and medical disorders such as endometriosis. Martin is among the most cited medical scientists in the Southern Hemisphere, with a number of citation classics including "Genes, culture and personality: An empirical approach" that he co-authored with Lindon Eaves and Hans Eysenck, "Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus" (Nature, and "Genetic and environmental contributions to alcohol dependence risk in a national twin sample".
Harren Jhoti is an Indian-born British structural biologist whose main interest has been rational drug design and discovery. He is president and chief executive officer (CEO) of biotechnology company Astex Pharmaceuticals ("Astex") which is located in Cambridge, United Kingdom.
Dr Ved Prakash Kamboj, FNASc., FNA is the president of the National Science Academy of India and ex-director, CDRI and CSIR Emeritus Scientist, Central Drug Research Institute (CDRI).
Melior Discovery, Inc. is a private biopharmaceutical company based in Exton, Pennsylvania, USA. The company specializes in drug repositioning and has established a proprietary phenotypic screening platform that it uses for this purpose. Melior also offers certain contract research organization (CRO) services comprising animal models representing different disease conditions. The Company has issued press releases disclosing partnerships with Pfizer, Merck & Co., Johnson & Johnson, and AstraZeneca, all citing the use of the company’s drug repositioning technology. Melior Discovery has also used its technology to discover its own drug candidates.
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.
Michael R. Hayden, is a Killam Professor of Medical Genetics at the University of British Columbia, the highest honour UBC can confer on any faculty member. Only four such awards have ever been conferred in the Faculty of Medicine. Dr. Hayden is also Canada Research Chair in Human Genetics and Molecular Medicine. Hayden is best known for his research in Huntington disease (HD).
Fatehpur is a village and gram panchayat in the Yamunanagar district of the Indian state of Haryana. Also known as Fatehpur-123, it comes under the jurisdiction of Jagadhri tehsil.
Vicki L. Sato is a retired professor of management practice at Harvard Business School and a professor of the practice in the department of molecular and cell biology at Harvard University. Since 2021, she has been a member of the President’s Council of Advisors on Science and Technology (PCAST).
John C. Lechleiter is an American businessman and chemist. He served as the President, Chief Executive Officer and Chairman of the Board of Directors of Eli Lilly and Company from April 2008 to December 2016. John Lechleiter's successor is David Ricks who assumed the role of president and CEO in January 2017. He is the eldest of nine children of Jeanne and John H. Lechleiter.
Trevor Mervyn Jones, CBE PhD DSc (Hon) FRCP FMedSci FBPhS FRSM FRSC FLSW is a visiting professor at King's College London, and a former Head of R&D, at Wellcome. He continues to have a distinguished career in the pharmaceutical and biotech industry as well as in academia.
Sir Stephen Philip Jackson, FRS, FMedSci is the Frederick James Quick Professor of Biology. He is a senior group leader at the Cancer Research UK Cambridge Institute and associate group leader at the Gurdon Institute, University of Cambridge.
Fátima Ferreira-Briza is a Brazilian-Austrian biologist, biochemist and educator. Since 2010, she has been Professor of Molecular Biology at the University of Salzburg, Austria, where, since October 2011, she has also been Vice-Rector for Research with responsibility for the Faculty of Natural Sciences.
Steven M. Paul is an American neuroscientist and pharmaceutical executive. As of 2021, Paul serves as the CEO, president and chairman of Karuna Therapeutics.
June Nasrallah is Barbara McClintock Professor in the Plant Biology Section of the School of Integrative Plant Science at Cornell University. Her research focuses on plant reproductive biology and the cell-cell interactions that underlie self-incompatibility in plants belonging to the mustard (Brassicaceae) family. She was elected to the US National Academy of Sciences in 2003 for this work and her contributions generally to our understanding of receptor-based signalling in plants.